Cell MedX Corp. Takes Leap of Faith On the Road to FDA Approval


It sure looks like modern medicine is taking a turn for the better in the new millennium with a much bigger focus now on preventative medicine and technology that heals, rather than masking a medical condition with pain relief or a slowing process for the condition in question.

Now, however, at every turn in the biotech space, we’re seeing educational institutions and development stage biotech companies revealing extremely promising technology that is aimed at fixing or preventing, rather than slowing a medical condition or simply just making it feel better for a while. Case in point – over the last several decades, a countless number of companies have come out with masterful ways of better delivering insulin for diabetics, but virtually no one had come out and said diabetes could be cured through proper diet and/or non-evasive technology up until recently. While the Internet has allowed nutritionists to take center stage with their well-researched diet curing claims for overweight diabetics around the world, a small development stage biotech company, Cell MedX Corp. (OTCQB: CMXC), is focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. The Company is at the leading edge in the development of devices that treat chronic and acute conditions for both clinical and self-management care. They’re literally pioneering safe, results oriented technologies combining electro-chemical applications and establishing new levels of treatment, known as cellular medicine for the treatment of diabetes and other life threatening diseases. The Company’s lead eBalance technology will form the basis for a product line that will be available to aid in the management of diabetes mellitus (T1DM and T2DM) and its complications, both as a professional clinic-based as well as a home use device. As Cell MedX Corp. explains – based on the science of bioelectric signals affecting epigenetic events, behavior of cells can be modified to affect tissue, organ, and organism level events. Cell MedX has developed a radically different and very promising device that is distinctly unlike the approaches currently in use or in the treatment pipeline. More than just a “me too” device or incremental improvement in an established realm, this technology, if proven through diligent research and development, could open a new category of diabetes care. The eBalance Technology is intended to expand the traditional healthcare model of diabetes management by enabling patients to manage their symptoms using a biosignal generating device that is simple to use, causes no discomfort, and can easily be incorporated into any lifestyle. Well, it appears the Company is very serious about its opportunity to further prove their technology in an effort to change the lives of millions around the world… Earlier this morning, the Company announced it has completed its registration process with the U.S. Food and Drug Administration (“FDA”), and has initiated an application process to receive FDA clearance for use of its eBalance device as Class II non-exempt device. The Company also announce its ongoing clinical observational trial (the “Trial”) is progressing as expected, and as of March 27th, 2017, the group of study participants had been increased to 21, with 18 subjects having received their first eBalance treatments. The Company expects that all 30 subjects will be initiated into the study by early April. Current Observational Clinical Trial assesses the impact of three months of eBalance therapy as an adjunct treatment, on HbA1c in Type 1 and Type 2 diabetics. The secondary endpoints of the Trial will observe changes from baseline and medical history in the following; Insulin sensitivity Diabetic neuropathy Diabetic foot pain and numbness Wound healing Blood pressure Kidney function Any other changes reported by patients Mr. McEnulty, the Company’s CEO, stated: “Our registration with the FDA is an exciting step forward, and I’m happy to see that our Observational Clinical Trial is also progressing as scheduled, which together will get us that much closer to reaching our end goal of helping people improve their lives and well-being.” As for CMXC and what it’s offering investors in the markets right now, all you have to do is look at a recent chart of the stock. After a very quiet 2016, shares of CMXC have peeked investors’ interest in dramatic fashion of late with its average daily volume continuing to pick up, along with its share price in recent weeks. If the CMXC chart is any indication of what’s to come, it’s probably prudent traders and investors consider picking up some stock after doing their own diligence, because based on what’s starting to shape up on the PR front for Cell MedX, today’s news may well be the beginning of a much stronger pipeline of news going forward.